Autonomix Medical, Inc. announced on June 5, 2025, that it received Ethics Committee authorization from the Ministry of Health of the Republic of Uzbekistan to open the clinical trial site for the follow-on phase of its proof-of-concept human clinical trial (PoC 2). This approval allows the company to expand its evaluation beyond severe pancreatic cancer pain.
The PoC 2 phase will now include pain management for additional visceral cancers, such as gall bladder, liver, and bile duct, as well as earlier-stage pancreatic cancer patients experiencing moderate to severe pain. This strategic expansion has the potential to double the addressable market for Autonomix's proprietary ablation technology.
Patient enrollment for the PoC 2 study is expected to commence in June 2025. This advancement builds on the promising results from the initial PoC 1 phase, which demonstrated significant pain reduction, substantial decreases in opioid use, and meaningful improvements in quality of life for late-stage pancreatic cancer patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.